Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

819 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Completed

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

NCT00938652

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Sedona, Arizona, United States
  • Research Site Jonesboro, Arkansas, United States
  • Research Site Alhambra, California, United States
View all 102 locations
View Trial Details
Completed

Triple Negative Breast Cancer Biomarker Study

NCT01111175

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +6 more
Locations
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Virginia Oncology Assocites Elizabeth City, North Carolina, United States
  • Northwest Cancer Specialists, P.C. Portland, Oregon, United States
  • Northwest Cancer Specialists, P.C. Portland, Oregon, United States
View all 18 locations
View Trial Details
Completed

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

NCT00540358

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Denver, Colorado, United States
  • Research Site Torrington, Connecticut, United States
  • Research Site Ocoee, Florida, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT04491942

Conditions
Adenoma, Adnexal Diseases, Advanced Bile Duct Carcinoma, +72 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555

Conditions
Bilateral Breast Carcinoma, Breast Diseases, Breast Neoplasms, +9 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

Conditions
Breast Diseases, Breast Neoplasms, Invasive Breast Carcinoma, +8 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913

Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Diseases, +8 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut, United States
View all 43 locations
View Trial Details
Active, Not Recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874

Conditions
Breast Carcinoma In Situ, Breast Carcinoma in Situ, Breast Diseases, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Southern Cancer Center PC-Daphne Daphne, Alabama, United States
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
View all 919 locations
View Trial Details

Related conditions